NPOT® technology elucidates the molecular MoA of Evodiamine’s antiartherosclerotic activity
Strasbourg, July 2018, Inoviem Scientific, in collaboration with Prof Atanas G. Atanasov, announces the publication of an original paper in Scientific Reports – Nature, on Evodiamine target and mechanism of action.
This publication entitled “Novel interactomics approach identifies ABCA1 as a direct target of Evodiamine, which increases macrophage cholesterol efflux” was released online on the 23rd of July. It provides evidence for identification of Evodiamine’s molecular target, thanks to Inoviem’s NPOT® technology.
Evodiamine is a bioactive alkaloid from fruits of Evodia rutaecarpa (Juss.) Benth. It is used in traditional Chinese medicine to treat among others headache, hypertension and mouth ulcers. Several pieces of evidence are showing its beneficial cardiovascular effects and potential weight-lowering properties. In light of its use by patients and consumers, and having in mind its potential applications in the context of obesity and hyperlipidemia, Nematic Protein Organization Technique (NPOT®) and subsequent surface plasmon resonance (SPR) experiments have been used by Inoviem Scientific to identify and validate the target of this natural chemical molecule. Evodiamine increases ABCA1 protein stability resulting in elevated cellular ABCA1 and increased cholesterol efflux. The elucidated mode of action explains the previously described antiartherosclerotic effect of evodiamine and allows a better understanding of its biological effects. This study validates the application of NPOT® as a highly promising interactomics approach to identify compounds’ molecular targets and elucidate their mode of action.